Solid Tumor Cancer Clinical Trial
Official title:
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors
The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed. SB-743921 is dosed by 1-hour intravenous infusion every 3 weeks. A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of the drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-743921. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
| Completed |
NCT00046111 -
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00119171 -
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04354064 -
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
|
||
| Recruiting |
NCT02103920 -
A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors
|
N/A | |
| Completed |
NCT00169520 -
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00085878 -
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00085904 -
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
|
Phase 1 | |
| Completed |
NCT06042400 -
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
|
N/A |